Soleno Therapeutics Target of Unusually High Options Trading (NASDAQ:SLNO)

Key Points

• Unusually high options activity: Traders purchased 6,832 call options on Wednesday, a 92% increase versus the typical daily volume of 3,560 calls.
• Legal overhang: Multiple shareholder‑rights firms have filed or are soliciting claimants in a securities class action covering Mar 26–Nov 4, 2025, with a May 5, 2026 lead‑plaintiff deadline, increasing near‑term selling pressure and uncertainty.
• Mixed fundamentals and analyst views: Soleno reported an EPS beat and strong liquidity, but brokers’ consensus is an average "Hold" (avg. price target $76.67); the stock trades around $52.93 with a $2.76B market cap and a P/E of 230.12.

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) was the target of unusually large options trading activity on Wednesday. Stock traders purchased 6,832 call options on the stock. This is an increase of 92% compared to the typical daily volume of 3,560 call options.

Institutional Investors Weigh In On Soleno Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Raymond James Financial Inc. acquired a new stake in shares of Soleno Therapeutics during the second quarter worth $25,000. Danske Bank A S acquired a new stake in shares of Soleno Therapeutics during the third quarter worth $27,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Soleno Therapeutics during the third quarter worth $37,000. Global Retirement Partners LLC lifted its stake in shares of Soleno Therapeutics by 519.0% during the fourth quarter. Global Retirement Partners LLC now owns 619 shares of the company's stock worth $29,000 after buying an additional 519 shares during the period. Finally, Quarry LP acquired a new stake in shares of Soleno Therapeutics during the third quarter worth $47,000. 97.42% of the stock is currently owned by institutional investors and hedge funds.

Key Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Company fundamentals and recent results provide some support — Soleno reported an EPS beat in its last quarter (Feb. 25) and shows strong liquidity ratios, which reduces immediate solvency risk for investors.
• Neutral Sentiment: Broker consensus sits at an average "Hold," reflecting mixed analyst views rather than a buy/sell conviction. Soleno Therapeutics, Inc. NASDAQ: SLNO Given Average Recommendation of "Hold" by Brokerages
• Neutral Sentiment: Market is watching for the company's upcoming quarterly earnings announcement — results or forward guidance could move the stock independently of the litigation headlines. Soleno Therapeutics (SLNO) Expected to Announce Quarterly Earnings on Wednesday
• Negative Sentiment: Multiple shareholder‑rights firms have filed or are soliciting claimants in a securities class action covering purchases from March 26, 2025 to Nov 4, 2025 and are urging investors to file by the May 5, 2026 lead‑plaintiff deadline — this increases legal overhang and short‑term selling pressure. SOLENO DEADLINE TODAY: ROSEN Announces Lead Plaintiff Deadline Pomerantz Investor Alert Hagens Berman Deadline Alert
• Negative Sentiment: High volume of firm solicitations and media notices magnifies perception of risk — even if claims are routine, litigation can mean legal costs, management distraction, and uncertain timing for resolution, which tends to cap near‑term upside.

Wall Street Analyst Weigh In

SLNO has been the topic of several analyst reports. Wells Fargo & Company set a $53.00 price target on shares of Soleno Therapeutics and gave the stock an "equal weight" rating in a report on Friday, April 17th. Robert W. Baird lowered shares of Soleno Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, April 6th. Lifesci Capital lowered shares of Soleno Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, April 6th. TD Cowen lowered shares of Soleno Therapeutics from a "buy" rating to a "hold" rating and cut their price target for the stock from $85.00 to $53.00 in a report on Tuesday, April 7th. Finally, Zacks Research lowered shares of Soleno Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, February 3rd. Three equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $76.67.

Soleno Therapeutics Stock Performance

Shares of NASDAQ:SLNO traded up $0.01 on Wednesday, hitting $52.93. 932,275 shares of the company were exchanged, compared to its average volume of 2,895,873. Soleno Therapeutics has a 1-year low of $29.43 and a 1-year high of $90.32. The stock's 50 day moving average price is $42.73 and its 200 day moving average price is $46.54. The company has a current ratio of 5.80, a quick ratio of 5.55 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $2.76 billion, a P/E ratio of 230.12 and a beta of -2.22.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.64 by $0.16. The company had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. Sell-side analysts predict that Soleno Therapeutics will post 3.67 EPS for the current year.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company's scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company's lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.